In section Market Quotes

EU Approves Amneal’s Adcomfo for Severe Allergic Asthma

Adcomfo, a treatment for severe persistent allergic asthma, has received marketing authorization from the European Commission, Amneal Pharmaceuticals said. The decision follows a positive opinion from a European Medicines Agency committee in September.

EU Approves Amneal’s Adcomfo for Severe Allergic Asthma

Developed by Kashiv BioSciences with Alvotech, the add-on treatment is also known as ADL-018/AVT23. Amneal acquired Kashiv in August.

Adcomfo received authorization from the United Kingdom Medicines and Healthcare products Regulatory Agency in March. Amneal said its application for the proposed biosimilar to Novartis’ XOLAIR remains under review in the United States.

Share:on TelegramXFacebook

Subscribe to our newsletter

Once a week — the best stories from our editors, no ads or push notifications. Delivered Sunday morning.

Comments (0)

Leave a comment

No comments yet. Be the first!